Tenon Medical Q2 revenue jumps on higher surgical procedure volume

Tenon Medical

13/08/2026 21:15

Overview
US medical device maker's Q2 revenue rose 127% yr/yr on higher surgical procedure volume
Q2 gross profit up 232% yr/yr, gross margin improved to 64% from 43%
Company closed $4.2 mln public offering and received FDA clearance for updated Catamaran system

Outlook
Company expects lower per-procedure costs following instrument upgrades to Catamaran SI Joint Fusion System
Tenon Medical plans to use offering proceeds for debt repayment, commercial expansion, and clinical research
Company focus for remainder of 2026 is accelerating product launches, expanding training, and controlling spending

Result Drivers
SURGICAL PROCEDURE VOLUME - Co said Q2 revenue growth was primarily driven by a significant increase in the number of surgical procedures, including SImmetry+ system contributions
GROSS MARGIN IMPROVEMENT - Co attributed 21-point gross margin increase to higher revenue and lower fixed costs, leading to further absorption of production overhead costs
FDA CLEARANCE IMPACT - FDA clearance for updated Catamaran system expected to reduce recurring per-procedure costs by shifting instruments from disposable to reusable

Company press release: ID:nACSqqtpKa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$1.28 mln
$1.54 mln (2 Analysts)
Q2 Net Loss
 
$4.05 mln
 
Q2 Operating Expenses
 
$4.17 mln
 
Q2 Operating Income
 
-$3.35 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Tenon Medical Inc is $91.88, about 1,529% above its August 12 closing price of $5.64

Reuters Recommended Reads
Aug 11 - Xtant Medical Q2 revenue falls on asset sales and lost license revenue
Aug 10 - TELA Bio Q2 revenue falls on lower OviTex PRS volumes, withdraws outlook
Aug 12 - Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)